NCT05116618View on ClinicalTrials.gov

Detection of Resistance Mechanisms in Cerebrospinal Fluid for EGFR-mutant, ALK- and ROS1-rearranged

WithdrawnOBSERVATIONAL
0
Timeline

Start Date

January 6, 2022

Primary Completion Date

September 15, 2022

Study Completion Date

September 15, 2022

Conditions
Non-Small Cell Lung Cancer
Interventions
DIAGNOSTIC_TEST

InVisionFirst-Lung ctDNA assay

An enhanced tagged/targeted-amplicon sequencing technology for detection of genomic alterations in 36 commonly mutated genes in plasma ctDNA with a sensitivity of 73.9% and specificity of 99.8%.

Trial Locations (3)

20057

Georgetown University, Washington D.C.

80045

Colorado Research Center, Aurora

90033

USC Norris Comprehensive Cancer Center, Los Angeles

Sponsors

Collaborators (1)

Inivata
All Listed Sponsors
collaborator

Inivata

INDUSTRY

lead

University of Colorado, Denver

OTHER

NCT05116618 - Detection of Resistance Mechanisms in Cerebrospinal Fluid for EGFR-mutant, ALK- and ROS1-rearranged | Biotech Hunter | Biotech Hunter